The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial

被引:22
作者
Chen, Lei [1 ]
Johnston, Joseph A. [1 ]
Kinon, Bruce J. [1 ]
Stauffer, Virginia [1 ]
Succop, Paul [2 ]
Marques, Tiago R. [3 ]
Ascher-Svanum, Haya [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Univ Cincinnati, Cincinnati, OH USA
[3] Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London WC2R 2LS, England
关键词
Positive symptoms; Negative symptoms; Trajectory interplay; Schizophrenia; TREATMENT RESPONSE TRAJECTORIES; DOUBLE-BLIND; SYNDROME SCALE; SCHIZOPHRENIC-PATIENTS; OLANZAPINE TRIAL; DEFICIT SYNDROME; CLINICAL-TRIALS; PLACEBO; HETEROGENEITY; HALOPERIDOL;
D O I
10.1186/1471-244X-13-320
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Schizophrenia is a highly heterogeneous disorder with positive and negative symptoms being characteristic manifestations of the disease. While these two symptom domains are usually construed as distinct and orthogonal, little is known about the longitudinal pattern of negative symptoms and their linkage with the positive symptoms. This study assessed the temporal interplay between these two symptom domains and evaluated whether the improvements in these symptoms were inversely correlated or independent with each other. Methods: This post hoc analysis used data from a multicenter, randomized, open-label, 1-year pragmatic trial of patients with schizophrenia spectrum disorder who were treated with first- and second-generation antipsychotics in the usual clinical settings. Data from all treatment groups were pooled resulting in 399 patients with complete data on both the negative and positive subscale scores from the Positive and Negative Syndrome Scale (PANSS). Individual-based growth mixture modeling combined with interplay matrix was used to identify the latent trajectory patterns in terms of both the negative and positive symptoms. Pearson correlation coefficients were calculated to examine the relationship between the changes of these two symptom domains within each combined trajectory pattern. Results: We identified four distinct negative symptom trajectories and three positive symptom trajectories. The trajectory matrix formed 11 combined trajectory patterns, which evidenced that negative and positive symptom trajectories moved generally in parallel. Correlation coefficients for changes in negative and positive symptom subscale scores were positive and statistically significant (P < 0.05). Overall, the combined trajectories indicated three major distinct patterns: 1) dramatic and sustained early improvement in both negative and positive symptoms (n = 70, 18%), 2) mild and sustained improvement in negative and positive symptoms (n = 237, 59%), and 3) no improvement in either negative or positive symptoms (n = 82, 21%). Conclusions: This study of symptom trajectories over 1 year shows that changes in negative and positive symptoms were neither inversely nor independently related with each other. The positive association between these two symptom domains supports the notion that different symptom domains in schizophrenia may depend on each other through a unified upstream pathological disease process.
引用
收藏
页数:10
相关论文
共 49 条
[1]   POSITIVE AND NEGATIVE SYMPTOMS OF SCHIZOPHRENIA - THEIR COURSE AND RELATIONSHIP OVER TIME [J].
ADDINGTON, J ;
ADDINGTON, D .
SCHIZOPHRENIA RESEARCH, 1991, 5 (01) :51-59
[2]  
ANDREASEN NC, 1982, AM J PSYCHIAT, V139, P297
[3]  
ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P784
[4]   The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms [J].
Arango, C ;
Buchanan, RW ;
Kirkpatrick, B ;
Carpenter, WT .
EUROPEAN PSYCHIATRY, 2004, 19 (01) :21-26
[5]   Distributional assumptions of growth mixture models: Implications for overextraction of latent trajectory classes [J].
Bauer, DJ ;
Curran, PJ .
PSYCHOLOGICAL METHODS, 2003, 8 (03) :338-363
[6]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[7]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[8]  
Buchanan RW, 1998, AM J PSYCHIAT, V155, P751
[9]  
CARPENTER WT, 1976, ARCH GEN PSYCHIAT, V33, P508
[10]  
CARPENTER WT, 1988, AM J PSYCHIAT, V145, P578